Catalogue

COVID-19: Updates on library services and operations.

Critical pathways to success in CNS drug development /
Neal R. Cutler ... [et al.].
imprint
Chichester, UK ; Hoboken, NJ : Wiley-Blackwell, 2010.
description
viii, 263 p.
ISBN
9781444330649
format(s)
Book
Holdings
More Details
added author
imprint
Chichester, UK ; Hoboken, NJ : Wiley-Blackwell, 2010.
isbn
9781444330649
contents note
The impending crisis in CNS drug development -- Animal models and procedures for CNS disorders -- Pre-clinical antecedents to early human clinical trials -- Biomarkers and surrogate markers in drug development -- Neuroimaging and cognitive assessments in early drug development -- Bridging and CSF studies -- A case study from pre-clinical to early clinical trials.
catalogue key
7146518
 
Includes bibliographical references and index.
A Look Inside
Reviews
Review Quotes
Review copy sent(x2) 25/05/11: Doody Enterprises, Inc.
To find out how to look for other reviews, please see our guides to finding book reviews in the Sciences or Social Sciences and Humanities.
Summaries
Long Description
Covering the latest advances in CNS drug development, this book will guide all those involved in pre-clinical to early clinical trials. The authors describe how recent innovations can accelerate the development of novel CNS compounds, improve early detection of efficacy and toxicity signals, and increase the safety of later-stage clinical trials.The current crisis in the drug development industry is critically reviewed, as well as the steps needed to correct the problems, including new government-backed regulations and industry-based innovations designed to accelerate CNS drug development in the future.Animal-based models of major CNS disorders are described in detail, and the ability of the latest in vitro and computer-based models to simulate CNS disease states and predict drug efficacy and side-effects are examined. Particular attention is given to the growing use of biomarkers and how they can be used effectively in early human trials as signals of potential drug efficacy, as well as the increasingly important role of imaging studies to guide dose selection. Cognitive assessments that can be useful indicators of effect in patient populations are also discussed.Written by a team of clinical scientists involved in CNS drug trials for over 20 years, and based on a wealth of drug development and clinical trial experience, Critical Pathways to Success in CNS Drug Developmentis full of practical advice for successfully designing and executing CNS drug trials, avoiding potential pitfalls, and complying with government regulations.
Main Description
Clinical Pathways to Success in CNS Drug Development provides a thorough overview of the critical early CNS drug development process for clinical scientists and reviews the latest models, technologies and regulations designed to improve and expedite the drug development process on each of the major CNS disorders. It includes a critical analysis of the lack of CNS specific drugs successfully brought to market and the steps required to remedy this problem. The book covers all of the initial stages of CNS drug development, from pre-clinical to early clinical trials, and includes all the latest technologies, methods, biomarkers, models and regulations designed to accelerate the early CNS drug development process, reduce overall costs, and improve drug safety and efficacy. It also discusses the many inherent difficulties in developing CNS-specific drugs, and describes the many technical and methodological advances used to circumvent these difficulties.
Main Description
Covering the latest advances in CNS drug development, this book will guide all those involved in pre-clinical to early clinical trials. The authors describe how recent innovations can accelerate the development of novel CNS compounds, improve early detection of efficacy and toxicity signals, and increase the safety of later-stage clinical trials. The current crisis in the drug development industry is critically reviewed, as well as the steps needed to correct the problems, including new government-backed regulations and industry-based innovations designed to accelerate CNS drug development in the future. Animal-based models of major CNS disorders are described in detail, and the ability of the latest in vitro and computer-based models to simulate CNS disease states and predict drug efficacy and side-effects are examined. Particular attention is given to the growing use of biomarkers and how they can be used effectively in early human trials as signals of potential drug efficacy, as well as the increasingly important role of imaging studies to guide dose selection. Cognitive assessments that can be useful indicators of effect in patient populations are also discussed. Written by a team of clinical scientists involved in CNS drug trials for over 20 years, and based on a wealth of drug development and clinical trial experience, Critical Pathways to Success in CNS Drug Development is full of practical advice for successfully designing and executing CNS drug trials, avoiding potential pitfalls, and complying with government regulations
Table of Contents
Acknowledgmentsp. vi
Forewordp. vii
The impending crisis in CNS drug developmentp. 1
Animal models and procedures for CNS disordersp. 14
Preclinical antecedents to early human clinical trialsp. 70
Biomarkers and surrogate markers in drug developmentp. 101
Neuroimaging and cognitive assessments in early drug developmentp. 167
Bridging and CSF studiesp. 187
A case study from preclinical to early clinical trialsp. 230
Indexp. 254
Table of Contents provided by Ingram. All Rights Reserved.

This information is provided by a service that aggregates data from review sources and other sources that are often consulted by libraries, and readers. The University does not edit this information and merely includes it as a convenience for users. It does not warrant that reviews are accurate. As with any review users should approach reviews critically and where deemed necessary should consult multiple review sources. Any concerns or questions about particular reviews should be directed to the reviewer and/or publisher.

  link to old catalogue

Report a problem